Scarica l'app Stockscreener
20.65
2.08%
0.42
Dopo l'orario di chiusura:
20.27
-0.38
-1.84%
Precedente Chiudi:
$20.23
Aprire:
$20.55
Volume 24 ore:
692.89K
Relative Volume:
1.29
Capitalizzazione di mercato:
$1.27B
Reddito:
-
Utile/perdita netta:
$-209.84M
Rapporto P/E:
-4.5186
EPS:
-4.57
Flusso di cassa netto:
$-6.73M
1 W Prestazione:
-0.05%
1M Prestazione:
-26.72%
6M Prestazione:
-17.70%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$19.59
$20.77
Intervallo di 1 settimana:
$19.59
$21.85
Portata 52W:
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
Nome
Damora Therapeutics Inc
Settore
Industria
Telefono
(781) 281-9020
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
20.65 | 1.28B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-03-25 | Iniziato | Evercore ISI | Outperform |
| 2026-02-17 | Iniziato | UBS | Buy |
| 2026-01-07 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Guggenheim | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | BofA Securities | Buy |
| 2020-11-23 | Iniziato | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Damora Therapeutics Advances CALR-Targeted Antibody Into Early Clinical Testing - TipRanks
CEO, President & Director of Damora Therapeutics Picks Up 2.5% More Stock - Simply Wall Street
DMRA Reiterates by Wedbush -- Price Target Maintained at $40 - GuruFocus
Damora Therapeutics (DMRA) CEO Jennifer Jarrett Buys 12,500 Shar - GuruFocus
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares - Investing.com
Form 4 Damora Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 4 Damora Therapeutics Inc For: 28 September - Investing.com India
Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing - marketscreener.com
Using personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. - Stock Titan
DMRA Maintained by Guggenheim -- Price Target Raised to $60.00 - GuruFocus
Guggenheim maintains Buy rating on Damora Therapeutics, $60 price target - TradingView
Guggenheim raises Damora Therapeutics price target on MF sales outlook By Investing.com - Investing.com Canada
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to S&P Global BMI Index - marketscreener.com
Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA) - Seeking Alpha
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Consolidates Near $31 as Shares Hold Within Trading RangeStrong Buy Stocks - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - Kalkine Media
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresPositive Surprise Momentum - dars.gov.et
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Inc Azioni (DMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):